Check out this guide to learn about the best Redstone builds for the beginners that will help you understand the basics of ...

Although Mojang has not provided a precise timeline for transitioning Minecraft to Vulkan, players and modders can begin testing the new renderer in Java Edition in ...

Minecraft fans should pay close attention to March 21, as developer Mojang plans to share some big news regarding the popular game.

How a game looks is one of its most important factors, especially in an age of photo-realism and ray-tracing. So, even if you're playing one of the most aesthetically uncomplicated videogames to come ...

Part of Minecraft's charm has always been its simple, blocky, pixelated aesthetic. With more items than ever and some retextures over the years, vanilla Minecraft looks slightly less grassroots than ...

Snapshots are one of the most anticipated updates in Minecraft as they come with features revealing the theme of the next major update. However, the ones that are released for April Fools' are a bit ...

CVS is launching a digital platform service called, Health 100 and Apple is coming out with more emojis for users to express themselves with.

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

It's now been confirmed that an "alpha" version of the next-gen Project Helix hardware will be shipped to developers in 2027, but there's no word on whether that's early or late in the year — so who ...

Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...